AstraZeneca vs Procter & Gamble: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Procter & Gamble side by side

1. 1837Procter & Gamble

   Company Founded in Cincinnati

   William Procter and James Gamble sign a partnership agreement on October 31, 1837, establishing Procter & Gamble in Cincinnati, Ohio, with combined capital of approximately 7,192 dollars.

2. 1862Procter & Gamble

   Civil War Army Contracts Fuel Expansion

   P&G wins contracts to supply the Union Army with soap and candles, generating significant revenue that enables manufacturing expansion and introduces millions of American soldiers to P&G products for the first time.

3. 1882Procter & Gamble

   Ivory Soap Launches Nationally

   Harley Procter and James Norris Gamble introduce Ivory soap, promoted as 99 and 44/100 percent pure and notable for its floating characteristic.

4. 1890Procter & Gamble

   Company Incorporates and Expands Nationally

   Procter & Gamble incorporates in Ohio with capital of 4.5 million dollars and begins building manufacturing capacity outside Cincinnati, establishing the operational infrastructure for national distribution that the Ivory soap advertising campaign had created…

5. 1911Procter & Gamble

   Crisco Shortening Introduced

   P&G launches Crisco vegetable shortening, the first hydrogenated vegetable oil product marketed to American consumers as an alternative to lard and butter.

6. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

7. 1931Procter & Gamble

   Brand Management System Invented

   P&G executive Neil McElroy writes a famous internal memo proposing that each brand have its own dedicated management team responsible for competing against all rivals including other P&G brands.

8. 1946Procter & Gamble

   Tide Detergent Launches

   P&G introduces Tide synthetic detergent, which rapidly becomes the best-selling laundry product in the United States and establishes the template for all future P&G brand development: superior product performance, heavy consumer advertising, and sustained mark…

9. 1961Procter & Gamble

   Pampers Diapers Introduced

   P&G introduces Pampers disposable diapers, transforming the infant care category and creating what will become one of the company's most globally significant brands.

10. 1993AstraZeneca

    Zeneca Group Spun Off from ICI

    Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

11. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

12. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

13. 2005Procter & Gamble

    Gillette Acquired for 57 Billion Dollars

    P&G completes the acquisition of Gillette Company for approximately 57 billion dollars in an all-stock transaction, adding Gillette razors, Braun appliances, Oral-B dental products, and Duracell batteries to the P&G portfolio.

14. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

15. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

16. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

17. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

18. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

19. 2014Procter & Gamble

    Portfolio Transformation Announced

    CEO A.G. Lafley announces P&G's plan to divest more than 100 brands and focus the company on approximately 80 core brands in ten product categories.

20. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

21. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

22. 2019Procter & Gamble

    Portfolio Simplification Completed

    P&G completes the brand portfolio simplification, having divested more than 100 brands and consolidated around approximately 65 core brands.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

26. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

27. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

28. 2024Procter & Gamble

    Fiscal Year 2024 Net Sales Reach Approximately 84 Billion Dollars

    P&G reports fiscal year 2024 net sales of $84.0 billion and net earnings attributable to P&G of about $14.9 billion, and raises its quarterly dividend 7% to $1.0065 per share, its 68th consecutive annual increase.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

33. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

34. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about AstraZeneca vs Procter & Gamble